Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04736745
Recruitment Status : Not yet recruiting
First Posted : February 3, 2021
Last Update Posted : February 3, 2021
Sponsor:
Information provided by (Responsible Party):
Ipsen

Brief Summary:
The purpose of the protocol, is to assess the safety and efficacy profile of IPN59011 compared to a placebo. IPN59011 is expected to work longer than product already marketed in the treatment of subjects with moderate to severe facial wrinkles.

Condition or disease Intervention/treatment Phase
Moderate Upper Facial Lines Severe Upper Facial Lines Drug: IPN59011 Drug: Azzalure Drug: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 424 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: For dose escalation part Sequential study model will be used. For the rest of the study parallel assignment will be used.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled Dose Escalation and Dose Finding Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines
Estimated Study Start Date : February 4, 2021
Estimated Primary Completion Date : December 15, 2023
Estimated Study Completion Date : December 15, 2023

Arm Intervention/treatment
Experimental: Dose escalation

One single injection of study medication (IPN59011 or Placebo) will be injected locally. IPN59011 is injected in a dose-escalation manner.

In total for this stage at least 40 subjects.

Drug: IPN59011
Powder and solvent for solution for injection

Drug: Placebo
Powder for solution for injection

Experimental: Dose ranging

Up to two IPN59011dose(s) groups will be included in parallel groups versus Azzalure group and placebo group. One single injection of study medication will be injected locally into several sites.

In total for this stage at least 70 subjects.

Drug: IPN59011
Powder and solvent for solution for injection

Drug: Azzalure
Powder for solution for injection

Drug: Placebo
Powder for solution for injection

Experimental: Additional dose ranging

Dose-ranging for three additional placebo-controlled parallel groups. One single injection of study medication will be injected locally into several sites, concomitantly and non-concomitantly.

In total for this stage at least 110 subjects.

Drug: IPN59011
Powder and solvent for solution for injection

Drug: Placebo
Powder for solution for injection

Experimental: Total dose for Upper Facial Lines

One single injection of study medication will be injected locally into Upper Facial Lines.

In total for this stage approximately 60 subjects.

Drug: IPN59011
Powder and solvent for solution for injection

Drug: Placebo
Powder for solution for injection




Primary Outcome Measures :
  1. Incidence of the Treatment-Emergent Adverse Events (TEAEs) at each dose for dose escalation [ Time Frame: from baseline until the end of study (9 months) ]
  2. Incidence of Serious Adverse Events (SAEs) at each dose for dose escalation [ Time Frame: from baseline until the end of study (9 months) ]
  3. Incidence of clinically significant Adverse Events (AEs) at each dose for dose escalation [ Time Frame: from baseline until the end of study (9 months) ]
  4. Incidence of AEs (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs) for dose escalation [ Time Frame: from baseline until the end of study (9 months) ]
  5. Presence of botulinum neurotoxin serotype A (BoNT-A) antibodies and IPN59011 antibodies and titres (binding and neutralizing) [ Time Frame: from baseline until the end of study (9 months) ]
  6. Response to treatment measured by the composite response of 2-grade improvement on investigator's live assessment (ILA) at maximum contraction. [ Time Frame: Day 29 ]
    ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs at maximum frown and at rest where 0 is "no lines are noticeable" and 3 is "lines are extremely pronounced".

  7. Response to treatment measured by the composite response of 2-grade improvement on subject's self-assessment (SSA) at maximum contraction. [ Time Frame: Day 29 ]
    SSA: a validated 4-point categorical scale to assess the appearance of their Glabellar Lines (GLs) at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles".


Secondary Outcome Measures :
  1. Response to treatment as measured by the reduction of ≥2 grades on the ILA at maximum contraction [ Time Frame: From the baseline to the end of the study (9 months) ]
  2. Response to treatment as achieved by a score of "none" or "mild" as measured by the ILA at maximum contraction [ Time Frame: From the baseline to the end of the study (9 months) ]
  3. Response to treatment as achieved by a score of "none" or "mild" as measured by the ILA at rest [ Time Frame: From the baseline to the end of the study (9 months) ]
  4. Response to treatment as measured by the reduction of ≥2 grades on the SSA at maximum contraction [ Time Frame: From the baseline to the end of the study (9 months) ]
  5. Response to treatment as achieved by a score of "none" or "mild" as measured by the SSA at maximum contraction [ Time Frame: From the baseline to the end of the study (9 months) ]
  6. Response to treatment as achieved by a score of "very satisfied" or "satisfied" on the Subject Level of Satisfaction (SLS) [ Time Frame: From the baseline to the end of the study (9 months) ]
  7. Duration of treatment response based on ILA and SSA at maximum contraction [ Time Frame: From the baseline to the end of the study (9 months) ]
  8. Face-Q (overall satisfaction with facial appearance) for Upper Facial Lines (UFL) [ Time Frame: Visits screening, Day 1, Day 15, Day 29, 3 months, 6 months, 9 months ]
  9. Time to onset of treatment response based on subject diary cards to evaluate the appearance of their lines. [ Time Frame: From Day 1 through Day 8 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of written informed consent prior to any study related procedures.
  • Female and male subjects between 18 and 65 years of age, inclusive (for dose escalation females only)
  • Moderate or severe (Grade 2 or 3) GL at maximum contraction at Baseline, as assessed by the ILA using a validated 4-point photographic scale.
  • Moderate or severe (Grade 2 or 3) GL at maximum contraction at Baseline, as assessed by the SSA using a validated 4-point categorical scale.
  • Moderate or severe (Grade 2 or 3) Forehead Lines (FHL) at maximum contraction and moderate to severe GL at maximum contraction at Baseline or moderate to severe (Grade 2 or 3) Lateral Canthal Lines (LCL) at maximum contraction (Stage as assessed by the ILA using a validated 4-point photographic scale).
  • Moderate or severe (Grade 2 or 3) FHL at maximum contraction and moderate to severe GL at maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL at maximum contraction (Stage as assessed by the ILA using a validated 4-point photographic scale).
  • Moderate or severe (Grade 2 or 3) FHL at maximum contraction and moderate to severe GL maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL at maximum contraction, as assessed by the by the SSA using a validated 4-point categorical scale.
  • Moderate or severe (Grade 2 or 3) FHL at maximum contraction and moderate to severe GL maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL at maximum contraction, as assessed by the by the SSA using a validated 4-point categorical scale.
  • Dissatisfied or very dissatisfied (Grade 2 or 3) with their lines at Baseline, as assessed by the subject's level of satisfaction.
  • A negative pregnancy test (for females of childbearing potential only). Non-childbearing potential is defined as postmenopausal for at least 1 year; surgical sterilisation at least 3 months before entering the study; or hysterectomy.
  • Subject has both the time and the ability to complete the study and comply with study instructions.

Exclusion Criteria:

  • Previous treatment with any Botox (BTX) serotype (for dose escalation at least) or any recent treatment (within the past 6 months prior to Baseline for the rest of the study) with any BTX serotype.
  • Any prior treatment with permanent fillers in the upper face including the GL, FHL and LCL area.
  • Any prior treatment with long lasting dermal fillers in the upper face including the GL area within the past 3 years and/or skin abrasions/resurfacing (whatever the interventional technic used) within the past 5 years, or photo rejuvenation or skin/vascular laser intervention within the 12 months prior to Baseline.
  • Any planned facial cosmetic surgery during the study.
  • A history of eyelid blepharoplasty or brow lift within the past 5 years.
  • An inability to substantially reduce GL by physically spreading them apart or lack of capacity to frown.
  • An active infection or other skin problems in the upper face including the GL, FHL and LCL area (e.g. acute acne lesions or ulcers).
  • Use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study treatment, including medications affecting bleeding disorders (e.g. antiplatelet agents and/or anticoagulants given for treatment or prevention of cardiovascular/cerebrovascular diseases).
  • Pregnant women, nursing women, premenopausal women or women of childbearing potential (i.e. not surgically sterile or 1 year postmenopausal) not willing to practice a highly effective form of contraception method at the beginning of the study, for the duration of the study and for a minimum of 12 weeks following last administration of study treatment. Highly effective methods of contraception are defined as methods of birth control which result in a low failure rate (less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, intrauterine devices, or vasectomised partner.
  • Male subjects who are not vasectomised and who have female partners of childbearing potential and are not willing to use condoms with spermicide throughout study participation for a minimum of 12 weeks following initial double-blind administration of the treatment.
  • Positive for hepatitis B antigen, or hepatitis C virus antibody, or for human immunodeficiency virus (HIV) or a diagnosis of acquired immunodeficiency syndrome.
  • A history of drug or alcohol abuse.
  • Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the half life is unknown within 30 days prior to the start of the study (prior to Baseline) and during the conduct of the study.
  • Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the subject's participation in the study.
  • Use of medications that affect neuromuscular transmission, such as curare-like nondepolarising agents, lincosamides, polymyxins, anticholinesterases and aminoglycoside antibiotics, within the past 30 days prior to Baseline.
  • A history of facial nerve palsy.
  • Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
  • Known allergy or hypersensitivity to BTX, or any excipients of IPN59011 or Azzalure, or allergy to cow's milk protein.
  • Any known medical condition that may put the subject at increased risk in regard to exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.)
  • The presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function), laboratory finding or circumstance that, in the judgment of the investigator, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
  • Any uncontrolled systemic disease or other significant medical condition considered as an exclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04736745


Contacts
Layout table for location contacts
Contact: Ipsen Recruitment Enquiries see email clinical.trials@ipsen.com

Sponsors and Collaborators
Ipsen
Investigators
Layout table for investigator information
Study Director: Ipsen Medical Director Ipsen
Layout table for additonal information
Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT04736745    
Other Study ID Numbers: D-FR-59011-001
2019-003268-33 ( EudraCT Number )
First Posted: February 3, 2021    Key Record Dates
Last Update Posted: February 3, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Where patient data can be anonymized, Ipsen will share all individual participant data that underlie the results reported in the published journal article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available
Time Frame: Data are available beginning 6 months and ending 5 years after the publication of the findings in a journal; after this time, only raw data may be available.
Access Criteria: Proposals should be submitted to DataSharing@ipsen.com and will be assessed by a scientific review board.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Facies
Disease Attributes
Pathologic Processes
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs